Business Overview: CIMG Inc. (Nasdaq: CIMG)

Executive Summary

CIMG Inc. (trading on Nasdaq under the symbol "IMG" since its October 2024 rebrand from NuZee, Inc./"NUZE") is a micro-cap holding company that has undergone one of the more dramatic strategic pivots in the small-cap Nasdaq universe over the past two years. What began in 2013 as NuZee — a specialty single-serve, pour-over coffee manufacturer serving U.S. and Japanese retail and co-packing customers — has, since mid-2024, divested its legacy coffee operations (including the sale of its Korean subsidiaries to its former CEO in June 2024) and re-domiciled its commercial focus almost entirely inside mainland China and Hong Kong. The company now operates three unrelated consumer/enterprise product lines under a single corporate umbrella: (1) Maca-root-derived functional foods and beverages, (2) a "Homology of Medicine and Food" line anchored by Huomao-branded exosome eye drops, and (3) distribution of AI-enabled GPU computing hardware to Chinese enterprise customers, including China Merchants Bank. For fiscal year 2025 (ended September 30, 2025), CIMG generated $10.3 million in revenue — a genuine, growing top line — but posted a net loss of $4.89 million against an accumulated deficit of roughly $87.2 million, and its auditor has issued a going-concern qualification. Revenue is dangerously concentrated (two customers = 96% of sales; two suppliers = ~97% of purchases), the company has repeatedly faced Nasdaq delisting notices in 2025, and it operates a 13-person, multi-entity structure spanning at least 13 PRC and non-PRC subsidiaries with partial (51%–90%) ownership stakes in several. CIMG is best understood not as a moated franchise but as a thinly capitalized, China-facing trading/distribution vehicle in the early, unproven stages of a business-model transplant — real revenue, real operating segments, effectively no durable competitive advantage.

1. Core Business Model & How They Work

CIMG's current model is that of a multi-line trading and distribution company rather than a manufacturer with proprietary technology. The company secures exclusive or preferential distribution/licensing rights to third-party-manufactured products (Maca beverages from a Chinese supplier base, Huomao-branded medical-adjacent skincare/eye-care products, and AI GPU hardware modules), then re-markets and re-sells them through wholesale, e-commerce, and enterprise-sales channels in Greater China and, more nascently, Southeast Asia. Its structure is a holding company (Nevada-incorporated, Nasdaq-listed) sitting atop a web of Hong Kong and Singapore intermediate holding entities, which in turn control (wholly or through 51%–90% equity interests) a set of PRC operating subsidiaries — Beijing Zhongyan, Henan Zhongyan, Shanghai Huomao, Beijing Xilin, Shenzhen Zhimeng, and others — the entities that actually book revenue from Chinese customers. This VIE-adjacent, multi-tier offshore structure is common among small U.S.-listed China-facing issuers and carries the associated risks around cash repatriation, PRC regulatory oversight (e.g., CSRC/cybersecurity filing requirements), and currency controls.

CIMG Inc. (Nevada, Nasdaq: IMG)
        │
   ┌────┴────────────────┐
Non-PRC HoldCos        PRC Operating Subs (13 total)
 - Wewin (FL, US)        - Beijing Zhongyan
 - DZR Tech (HK)         - Henan Zhongyan
 - CIMG Pte (Singapore)  - Shanghai Huomao
 - Braincon (HK)         - Beijing Xilin
                         - Shenzhen Zhimeng, others
        │                         │
   Distribution rights      Revenue-generating
   & brand licenses         operations (51-90% owned)

Revenue is earned as the spread between what CIMG pays its Maca/health-product/GPU-hardware suppliers and what it charges downstream retail, wholesale, and enterprise buyers, supplemented by digital-marketing-driven direct sales through platforms such as TikTok, Alibaba.com, Tencent, and JD.com.

2. Business Segments

The mix shift is striking: as recently as the FY2024 10-K, Maca products were the headline growth story (target of 25,000 convenience-store placements and 300+ vending machines); one year later, Maca contributes barely more than a rounding error while an entirely new "Homology of Medicine and Food" line (eye drops) and a GPU-distribution line together generate 98.6% of revenue. This pattern — rapid segment reshuffling within 12–18 months — is a hallmark of an opportunistic, deal-driven small-cap rather than an operator executing a stable long-term roadmap.

3. Product Portfolio & Revenue Drivers

• Maca Series: Maca Peptide Coffee (sugar-free, medium-roast functional coffee), Maca-Noni energy drink, Maca Purified Powder, and Maca Wine, sourced under an exclusive three-year (July 2024–July 2027) distribution agreement with Hangzhou Yikang Yimei Health Technology Co., Ltd. for the "Kangduoyuan" brand, with raw maca cultivated in Yunnan, China and marketed against Andes-mountain provenance positioning.
• Homology of Medicine and Food (Huomao): The clear current revenue engine, led by exosome eye drops marketed for digital-eye-strain relief and dryness — a direct-to-consumer wellness product riding China's "medicine-food homology" regulatory and cultural category, sold alongside other Huomao-branded items.
• Computing Power Products: GPUs integrated with AI data-processing modules, sold to Chinese enterprise buyers including at least one large financial institution (China Merchants Bank). CIMG functions here as a hardware integrator/reseller riding China's domestic AI-infrastructure buildout, not as a chip designer or fab.

Revenue quality is undermined by extreme concentration: two customers accounted for 60% and 36% of FY2025 revenue (96% combined), and two suppliers for 60.2% and 36.5% of purchases (~97% combined) — meaning the loss of a single counterparty on either side of the ledger could impair the majority of the business overnight.

4. Competitive Landscape

CIMG explicitly frames its edge as "digital marketing capabilities," premium ingredient sourcing narrative, and management experience — soft, replicable claims rather than structural advantages. In GPU distribution specifically, the company competes in a segment where Chinese policy is actively favoring large domestic semiconductor and systems-integration champions, a dynamic that structurally disadvantages a 13-employee, sub-$20-million-market-cap distributor.

5. Strategic Strengths & Moats vs. Strategic Risks

Strengths: A Nasdaq listing (even if precarious) gives CIMG access to U.S. capital markets unavailable to most Chinese SME competitors; the exclusive Kangduoyuan distribution contract provides at least contractual (if not durable) category access through mid-2027; and the pivot into the Huomao/exosome eye-drop line has already produced real, fast-growing revenue.

Risks: (1) Going-concern doubt from the auditor and an $87.2 million accumulated deficit against ~$10 million of revenue; (2) 96%/97% customer and supplier concentration; (3) a fragmented, multi-tier PRC/HK/Singapore corporate structure with partial (51%–90%) ownership of key operating subsidiaries, raising governance and consolidation-risk questions; (4) repeated 2025 Nasdaq deficiency notices — the company remains subject to a Rule 5550(a)(2) bid-price compliance deadline and a Mandatory Panel Monitor through November 14, 2026; (5) full exposure to PRC cybersecurity, overseas-listing, and capital-control regulation; and (6) a demonstrated willingness to change its entire business identity (coffee → Maca → eye drops/GPUs) inside 24 months, which makes forward revenue and strategy difficult to underwrite.

6. Financial Overview & Performance Matrix

Net losses narrowed year-over-year even as revenue scaled meaningfully, suggesting some operating leverage from the new product lines, but the balance sheet remains deeply impaired by a nine-figure accumulated deficit, and management has explicitly stated it will need additional financing to fund operations over the next twelve months — a dilution risk for existing shareholders.

7. Summary Conclusion

CIMG Inc. is a real, revenue-generating operating company with an actual, current SEC Form 10-K (fiscal year ended September 30, 2025, filed February 2026) — it is not a shell, SPAC, ETF, or foreign private issuer filing a 20-F. But its investment profile is that of a speculative, high-risk turnaround/reinvention story rather than a franchise with defensible economics. The company has shed its original coffee business, repeatedly reallocated its commercial focus across unrelated categories (functional beverages, medical-adjacent eye care, AI hardware distribution), and now depends on a small number of Chinese counterparties for nearly all of its revenue and supply, all while carrying a going-concern qualification and unresolved Nasdaq listing-compliance obligations. Any equity-research treatment of CIMG should weight execution, financing, and China-regulatory risk far more heavily than product-level competitive analysis, and should treat reported segment revenue mix as unstable rather than a durable baseline for forecasting.